El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 

Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation

dc.contributor.authorRiera i Escalé, Antoni
dc.contributor.authorDonoghue, Craig
dc.contributor.authorCubillos Rojas, Mónica
dc.contributor.authorGutierrez Prat, Núria
dc.contributor.authorSánchez Zarzalejo, Carolina
dc.contributor.authorVerdaguer i Espaulella, Xavier
dc.contributor.authorNebreda, Àngel R.
dc.date.accessioned2025-04-04T14:16:08Z
dc.date.available2025-04-04T14:16:08Z
dc.date.issued2020-06-18
dc.date.updated2025-04-04T14:16:09Z
dc.description.abstractWe report the design of hetero-bifunctional small molecules that selectively target p38α and p38β for degradation. These proteolysis targeted chimeras (PROTACs) are based on an ATP competitive inhibitor of p38α and p38β, which is linked to thalidomide analogues to recruit the Cereblon E3 ubiquitin ligase complex. Compound synthesis was facilitated by the use of a copper catalyzed 'click' reaction. We show that optimization of the linker length and composition is crucial for the degradation-inducing activity of these PROTACs. We provide evidence that these chemical compounds can induce degradation of p38α and p38β but no other related kinases at nanomolar concentrations in several mammalian cell lines. Accordingly, the PROTACs inhibit stress and cytokine-induced p38α signaling. Our compounds contribute to understanding the development of PROTACs, and provide a useful tool to investigate functions of the p38 MAPK pathway and its involvement in diseases.
dc.format.extent1 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec703800
dc.identifier.issn0223-5234
dc.identifier.urihttps://hdl.handle.net/2445/220267
dc.language.isoeng
dc.publisherElsevier Masson SAS
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.ejmech.2020.112451
dc.relation.ispartofEuropean Journal of Medicinal Chemistry, 2020, vol. 201, p. 112451
dc.relation.urihttps://doi.org/10.1016/j.ejmech.2020.112451
dc.rights(c) Elsevier Masson SAS, 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Química Inorgànica i Orgànica)
dc.subject.classificationMolècules
dc.subject.classificationProteïnes quinases
dc.subject.otherMolecules
dc.subject.otherProtein kinases
dc.titleOptimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
231456.pdf
Mida:
2.69 MB
Format:
Adobe Portable Document Format